Lupus Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Mendelian Causes of Autoimmunity: the Lupus Phenotype
AbstractSystemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterized by its large heterogeneity in terms of clinical presentation and severity. The pathophysiology of SLE involves an aberrant autoimmune response against various tissues, an excess of apoptotic bodies, and an overproduction of type-I interferon. The genetic contribution to the disease is supported by studies of monozygotic twins, familial clustering, and genome-wide association studies (GWAS) that have identified numerous riskloci. In the early 70s, complement deficiencies led to the description of familial forms of SLE caused by ...
Source: Journal of Clinical Immunology - April 15, 2024 Category: Allergy & Immunology Source Type: research

Systemic lupus erythematosus combined with Wilson ’s disease: a case report and literature review
Systemic lupus erythematosus (SLE) and Wilson ’s disease (WD) are both systemic diseases that can affect multiple organs in the body. The coexistence of SLE and WD is rarely encountered in clinical practice, ma... (Source: BMC Pediatrics)
Source: BMC Pediatrics - April 15, 2024 Category: Pediatrics Authors: Zhenle Yang, Qian Li, Suwen Liu, Zihan Zong, Lichun Yu and Shuzhen Sun Tags: Case Report Source Type: research

Roles of IRF4 in various immune cells in systemic lupus erythematosus
Int Immunopharmacol. 2024 Apr 13;133:112077. doi: 10.1016/j.intimp.2024.112077. Online ahead of print.ABSTRACTInterferon regulatory factor 4 (IRF4) is a member of IRF family of transcription factors which mainly regulates the transcription of IFN. IRF4 is restrictively expressed in immune cells such as T and B cells, macrophages, as well as DC. It is essential for the development and function of these cells. Since these cells take part in the homeostasis of the immune system and dysfunction of them contributes to the initiation and progress of systemic lupus erythematosus (SLE), the roles of IRF4 in the SLE development bec...
Source: International Immunopharmacology - April 14, 2024 Category: Allergy & Immunology Authors: Ze Xiu Xiao Rongzhen Liang Nancy Olsen Song Guo Zheng Source Type: research

Accumulation of Microvascular Target Organ Damage in Systemic Lupus Erythematosus Patients Is Associated with Increased Cardiovascular Risk
Conclusions: Our study showed for the first time that SLE patients exhibit a greater number of cases of TOD. The accumulation of TOD was associated with increased CV risk. Clinicians dealing with SLE should be aware and seek microvascular alterations.PMID:38610905 | DOI:10.3390/jcm13072140 (Source: Atherosclerosis)
Source: Atherosclerosis - April 13, 2024 Category: Cardiology Authors: Nikolaos Koletsos Antonios Lazaridis Areti Triantafyllou Panagiota Anyfanti Stamatina Lamprou Anastasia Stoimeni Nikolaos G Papadopoulos Evaggelia-Evdoxia Koravou Eugenia Gkaliagkousi Source Type: research

Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study
CONCLUSIONS: Telitacicept treatment reduced disease severity in patients with LN. The initial clinical trial provided supportive evidence for the effectiveness and safety of Telitacicept as a viable treatment option for LN, allowing a reduction in the daily glucocorticoid intake while maintaining a good safety profile, and improving hypocomplementation in LN management.PMID:38613741 | DOI:10.1007/s10157-024-02501-x (Source: Herpes)
Source: Herpes - April 13, 2024 Category: Infectious Diseases Authors: Xiaolu Huang Fuan Lin Hongpu Chen Source Type: research

Dawn of CAR-T cell therapy in autoimmune diseases
Chin Med J (Engl). 2024 Apr 12. doi: 10.1097/CM9.0000000000003111. Online ahead of print.ABSTRACTChimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythema...
Source: Chinese Medical Journal - April 13, 2024 Category: General Medicine Authors: Yuxin Liu Minghao Dong Yunhui Chu Luoqi Zhou Yunfan You Xiaowei Pang Sheng Yang Luyang Zhang Lian Chen Lifang Zhu Jun Xiao Wei Wang Chuan Qin Daishi Tian Source Type: research

Accumulation of Microvascular Target Organ Damage in Systemic Lupus Erythematosus Patients Is Associated with Increased Cardiovascular Risk
Conclusions: Our study showed for the first time that SLE patients exhibit a greater number of cases of TOD. The accumulation of TOD was associated with increased CV risk. Clinicians dealing with SLE should be aware and seek microvascular alterations.PMID:38610905 | PMC:PMC11012611 | DOI:10.3390/jcm13072140 (Source: Atherosclerosis)
Source: Atherosclerosis - April 13, 2024 Category: Cardiology Authors: Nikolaos Koletsos Antonios Lazaridis Areti Triantafyllou Panagiota Anyfanti Stamatina Lamprou Anastasia Stoimeni Nikolaos G Papadopoulos Evaggelia-Evdoxia Koravou Eugenia Gkaliagkousi Source Type: research

Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study
ConclusionsTelitacicept treatment reduced disease severity in patients with LN. The initial clinical trial provided supportive evidence for the effectiveness and safety of Telitacicept as a viable treatment option for LN, allowing a reduction in the daily glucocorticoid intake while maintaining a good safety profile, and improving hypocomplementation in LN management. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - April 13, 2024 Category: Urology & Nephrology Source Type: research

Standing on Shoulders: Interferon Research From Viral Interference to Lupus Pathogenesis and Treatment
The discovery of interferon in the 1950s represents much more than the identification of the first cytokine and the key mediator of antiviral host defense. Defining the molecular nature and complexity of the type I interferon family, as well as its inducers and molecular mechanisms of action, was the work of investigators working at the highest level and producing insights of great consequence. Current knowledge of receptor –ligand interactions, cell signaling, and transcriptional regulation derives from studies of type I interferon. It is on the shoulders of the giants who produced that knowledge that others stand and h...
Source: Arthritis and Rheumatology - April 12, 2024 Category: Rheumatology Authors: Mary K. Crow, Mikhail Olferiev, Kyriakos A. Kirou Tags: Review Source Type: research

Calcineurin inhibitors experience in unplanned pregnancies with active lupus disease: A retrospective observational study
CONCLUSION: This study reveals that tacrolimus can be effectively used in unplanned pregnancies with active lupus disease, providing favorable maternal and fetal outcomes. The findings emphasize the importance of considering CNIs, particularly tacrolimus, in the management of SLE pregnancies, even in cases of unplanned pregnancies with a history of lupus nephritis.PMID:38606855 | DOI:10.5414/CP204528 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - April 12, 2024 Category: Drugs & Pharmacology Authors: İbrahim Vasi Derya Y ıldırım R ıza Can Kardaş Burcug ül Kaya Rahime Duran Gizem Tu ğçe Alp Hazan Karadeniz Asl ıhan Avanoğlu Güler Hamit K üçük Berna G öker Abdurrahman Tufan Mehmet Akif Öztürk Abdulsamet Erden Source Type: research